|By Marketwired .||
|May 22, 2014 09:00 AM EDT||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/22/14 -- Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) reports that the recent positive results in the Company's anticancer program have driven an increase in the Company's activities, in order to more rapidly capitalize on our findings and advance our innovative program to generate clinical interest and deal-making. We are building on recent results with collaborators in which we have demonstrated that modifications of our protein delivery system substantially increase antitumor activity and retard tumor growth in animals.
The Company is pursuing R&D that is advancing on three fronts to maximize possibilities for successful drug development and deal making. First, conjugates of its protein delivery system bearing chemotherapeutic drugs have been prepared and are currently being tested in animal models. Second, the antitumor activity of the protein, which itself has been shown to retard tumor growth, has been substantially increased (as reported for Series 1) by modifications that enhance affinity to the target biomarker on cancer cells, and thus retard tumor growth in animals. The encouraging affinity patterns to tumor cells that have been observed with members of Series I, have also been observed with Series 2, and series 3 is being readied for testing. Thirdly, besides our robust chemical modification capability, we have added recombinant DNA techniques to generate mutant fusion proteins that are now being produced and chemically modified. Such recombinantly generated proteins have been designed to allow for application of the full array of APC enhancements to the protein delivery system and to further strengthen our proprietary patent estate, which has been the subject of recent filings.
Further, the Company is involved in expanding access to equipment and instrumentation to cover the current needs of Company scientists who have been vigorously engaged in scaling up quantities of materials for multi-dose animal testing by our collaborators, in addition to their normal R&D activities. To more rapidly advance the program and provide increased support to our in-house efforts, contracts with our academic collaborators have been extended and will be announced shortly.
Besides ongoing work with fibrosarcoma cancer cell lines, testing in animal models in breast cancer have begun and an ovarian cancer cell line has been acquired, and still other possibilities are being considered. During the next several weeks results from biological testing are expected that will provide an indication as to which of our candidate molecules are appropriate for treating a specific cancer type.
Alexander Krantz, President and Chief Executive Officer of APC, said "The Company while thoroughly engaged in anti-cancer research, an immensely critical area of unmet needs, is focused on cancer immunotherapy, arguably the most exciting and promising area in current cancer research. From our innovative program, we have generated an ever increasing number of drug candidates, many of which are being tested to evaluate their potential as monotherapies and in combination immunotherapy. Advanced Proteome Therapeutics should be well-positioned to positively impact this vital area of therapeutic need which provides the optimal balance of costs and benefits."
APC has been applying its Foundation Trinity(TM) Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
Advanced Proteome Therapeutics Corporation
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Analytic. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
Apr. 27, 2017 10:30 PM EDT Reads: 1,258
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
Apr. 27, 2017 10:30 PM EDT Reads: 2,441
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Apr. 27, 2017 10:15 PM EDT Reads: 1,444
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Apr. 27, 2017 10:15 PM EDT Reads: 2,636
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Apr. 27, 2017 10:15 PM EDT Reads: 9,223
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Apr. 27, 2017 10:00 PM EDT Reads: 2,037
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Apr. 27, 2017 09:45 PM EDT Reads: 881
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...
Apr. 27, 2017 09:30 PM EDT Reads: 1,888
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Apr. 27, 2017 09:15 PM EDT Reads: 1,260
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Apr. 27, 2017 09:15 PM EDT Reads: 9,102
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls ...
Apr. 27, 2017 09:15 PM EDT Reads: 3,269
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Apr. 27, 2017 09:15 PM EDT Reads: 7,290
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
Apr. 27, 2017 08:45 PM EDT Reads: 2,482
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Apr. 27, 2017 08:15 PM EDT Reads: 724
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
Apr. 27, 2017 08:00 PM EDT Reads: 1,132